NCT04670445Completed
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
Source: ClinicalTrials.gov · Last updated 25 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer. The intervention is an educational video and question prompt list (QPL) to promote communication between patients, caregivers, and the oncology team about the risks and benefits of immunotherapy.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 199 (actual)
- First submitted
- 3 Dec 2020
- Start date
- 23 Jan 2021
- Primary completion date
- 23 Mar 2023
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- Head and neck cancer, Mesothelioma, Kidney cancer, Bladder cancer, Melanoma, Endometrial cancer, Cervical cancer, Lung cancer, Metastatic breast cancer, Colorectal cancer, Liver and biliary tract cancer, Gastric and esophageal cancer
- NCT number
- NCT04670445
What you commit to
- Study type: Interventional
- Participants enrolled: 199
- From 23 Jan 2021 to the primary completion date, 23 Mar 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Major psychiatric condition or comorbid illness that prohibits participation in the study
- Cognitive impairment that prohibits provision of informed consent or participation in the study
Other
- Pregnant women
- Prisoners
Who the study is looking for
- All participants (Patients and Caregivers)-Table 1
- Age 18 or older
- Ability to read and respond in English
- Patient Inclusion Criteria (in addition to Table 1)
- Receiving care in the MGH Cancer Center
- Diagnosis of advanced (stage IV) melanoma or advanced, incurable lung cancer, including stage IV non-small cell lung cancer (NSCLC), unresectable stage III NSCLC, extensive-stage small cell lung cancer.
- Plan to initiate immunotherapy with an ICI (pembrolizumab, nivolumab, ipilimumab, atezolizumab or combination), per clinician documentation in the electronic health record or study staff communication with clinician
- Caregiver Inclusion Criteria (in addition to Table 1)
- Identified as "a supportive person involved in their cancer care" by a patient enrolled in the study
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.